Scienza e Tecnologia
Glycomics/ Glycobiology Market worth $3.7 billion by 2027 - Exclusive Report by MarketsandMarkets™
Based on product, the glycomics/glycobiology market is segmented into enzymes, kits, instruments, carbohydrates and reagents & chemicals. In 2021, the highest share of the market is held by enzyme segment. The consumable nature of enzymes and wide application in r&d activities and drug discovery accounts for their highest share.
The drug discovery & development segment accounted for the largest share of the market in 2021. This is attributed to due to increasing R&D investment by pharmaceutical & biotechnology companies for drug discovery research and increasing demand for new therapeutics.
North America is estimated to be the fastest-growing segment of the market. The growth of the glycomics/glycobiology market in this region is driven by the presence of prominent market players offering glycomics products, increasing focus on glycomics research and its application in drug development and availability of research infrastructure in the US.
Key players in the glycomics/glycobiology market are Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA ( Germany ), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, ( Japan ), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. ( Japan ), Bruker Corporation (US), Shimadzu Corporation ( Japan ), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag ( France ), Kode Biotech Limited ( New Zealand ), Glyxera GmBH ( Germany ), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group ( Italy ), Asparia Glycomics ( Spain ) and Ray Biotech Life Inc. (US).
Research Reports & Consulting
Global Forecasts to 2029
Global Forecasts to 2026
Global Forecasts to 2026
Global Forecasts to 2025
Global Forecasts to 2025
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/glycobiology-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/glycobiology.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glycomics-glycobiology-market-worth-3-7-billion-by-2027---exclusive-report-by-marketsandmarkets-301665889.html